CDC45 Antibody

What is CDC45 and why is it important in cellular research?

CDC45 (also known as CDC45L, CDC45L2, MGORS7, PORC-PI-1) is a cell division control protein that plays a crucial role in DNA replication initiation. It functions as a core component of the CMG helicase complex that unwinds template DNA during replication and forms the foundation upon which the replisome is built . CDC45 expression is tightly associated with proliferating cell populations, making it particularly valuable for studying cell cycle regulation, DNA replication processes, and cancer biology .

What applications are CDC45 antibodies commonly used for?

CDC45 antibodies are primarily utilized in Western Blotting (WB), Immunohistochemistry on paraffin-embedded tissues (IHC-P), Immunocytochemistry/Immunofluorescence (ICC/IF), Immunoprecipitation (IP), and Flow Cytometry (FCM) . These applications allow researchers to detect endogenous levels of CDC45 protein, examine its localization during various cell cycle phases, and study its interactions with other replication proteins.

How can I validate the specificity of a CDC45 antibody?

To validate CDC45 antibody specificity, researchers should:

• Use positive control cell lines with known CDC45 expression (e.g., proliferating cancer cell lines like 293T, Jurkat, K562)

• Include negative controls such as quiescent, terminally differentiated, or senescent cells where CDC45 is absent

• Verify the detection of a single band at approximately 65-66 kDa in Western blots

• Perform siRNA knockdown experiments followed by Western blotting to confirm signal reduction

• Compare staining patterns with published literature to ensure expected nuclear localization during S phase

What fixation and antigen retrieval methods are most effective for CDC45 antibody in IHC applications?

For optimal CDC45 detection in IHC applications, heat-mediated antigen retrieval is recommended prior to commencing the staining protocol . Most protocols use formalin-fixed, paraffin-embedded (FFPE) tissues with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) for antigen retrieval. Tissue sections typically require 15-20 minutes of heat-mediated retrieval to expose CDC45 epitopes effectively. Since CDC45 is a nuclear protein involved in DNA replication, nuclear staining patterns should be observed in proliferating cells, particularly in tumor tissues which often show higher CDC45 expression compared to normal tissues .

What are the optimal dilutions and incubation conditions for CDC45 antibodies in different applications?

Optimal dilutions and conditions vary by application and specific antibody:

• Western Blotting: Typically 1:1000 dilution with overnight incubation at 4°C

• IHC-P: Generally 1:100 dilution with 1-2 hour incubation at room temperature or overnight at 4°C

• ICC/IF: Usually 1:100-1:500 dilution with 1-2 hour incubation at room temperature

• IP: Often 2-5 μg of antibody per 1 mg of total protein lysate

These recommendations should be optimized for each experimental setup, as different antibody clones and experimental conditions may require adjustment.

How should cellular samples be prepared to maximize CDC45 detection?

To maximize CDC45 detection:

• Use actively proliferating cell populations as CDC45 is absent in quiescent, terminally differentiated, and senescent cells

• Consider cell synchronization techniques to enrich for S-phase cells when CDC45 levels are highest

• For Western blotting, use RIPA or NP-40 based lysis buffers with protease inhibitors

• Include phosphatase inhibitors if studying CDC45 phosphorylation status

• For IF/ICC applications, fix cells with 4% paraformaldehyde followed by permeabilization with 0.1-0.5% Triton X-100

• When examining tissue samples, tumor tissues often show stronger staining than corresponding normal tissues due to higher proliferation rates

How can CDC45 antibodies be used to study the assembly and function of the CMG helicase complex?

CDC45 antibodies can be effectively utilized to study CMG helicase complex through several approaches:

• Co-immunoprecipitation (Co-IP) experiments:

  • Use CDC45 antibodies to pull down CDC45 and analyze associated proteins (MCM2-7, GINS) by Western blot

  • Perform reciprocal Co-IPs with antibodies against MCM proteins or GINS components

  • Apply crosslinking prior to IP to preserve transient interactions

• Chromatin Immunoprecipitation (ChIP) assays:

  • Utilize CDC45 antibodies to identify DNA replication origins where the CMG complex assembles

  • Perform sequential ChIP (re-ChIP) with antibodies against other replication factors to confirm co-occupancy

• Proximity ligation assays (PLA):

  • Combine CDC45 antibodies with antibodies against other CMG components to visualize protein-protein interactions in situ

  • Map the spatial and temporal assembly of the CMG complex throughout the cell cycle

These approaches can reveal crucial insights into the mechanisms underlying replication initiation and elongation processes .

What are the considerations for using CDC45 antibodies in cancer research applications?

When using CDC45 antibodies in cancer research, researchers should consider:

• Expression patterns:

  • CDC45 protein levels are consistently higher in cancer-derived cells compared to primary human cells

  • Tumor tissues show preferential staining with CDC45-specific antibodies

• Methodological approaches:

  • Use CDC45 as a potential proliferation marker alongside established markers like Ki-67 or PCNA

  • Compare CDC45 expression levels across different tumor grades and stages

  • Correlate CDC45 expression with patient outcomes through tissue microarray analysis

• Experimental design:

  • Include appropriate cancer cell lines with different proliferation rates

  • Use paired normal and tumor tissue samples from the same patient when possible

  • Consider the relationship between CDC45 and other cell cycle regulators

• Interpretation challenges:

  • Account for heterogeneity within tumor samples

  • Consider cell cycle phase distribution when interpreting results

  • Differentiate between CDC45 expression changes due to proliferation versus cancer-specific alterations

This approach can yield valuable insights into the potential of CDC45 as a novel proliferation marker in cancer biology .

How do CDC45 protein levels compare to MCM proteins, and what implications does this have for experimental design?

CDC45 is significantly less abundant than minichromosome maintenance (MCM) proteins in human cells . This differential expression has important implications for experimental design:

• Detection sensitivity:

  • Higher antibody concentrations or more sensitive detection methods may be required for CDC45 compared to MCM proteins

  • Signal amplification techniques may be necessary for certain applications

• Sample preparation:

  • Protein enrichment methods may be beneficial when studying CDC45

  • Cell synchronization can help maximize CDC45 detection during S phase

• Experimental interpretation:

  • The lower abundance of CDC45 supports the concept that origin binding of CDC45 is rate-limiting for replication initiation

  • When studying replication complex assembly, consider the stoichiometric relationship between CDC45 and MCM proteins

  • Quantitative comparisons between CDC45 and MCM proteins require careful normalization

This relative abundance differential provides a biological basis for CDC45's role as a limiting factor in replication initiation and should inform experimental approaches .

What are common challenges when using CDC45 antibodies and how can they be addressed?

Common challenges when working with CDC45 antibodies include:

• Weak signal in Western blots:

  • Increase antibody concentration or extend incubation time

  • Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Enrich for S-phase cells when CDC45 expression is highest

  • Concentrate protein samples or load more protein per lane (up to 30-50 μg)

• Background or non-specific staining in IHC/ICC:

  • Optimize blocking conditions (try 5% BSA or 5-10% normal serum)

  • Increase washing steps in duration and number

  • Reduce primary antibody concentration

  • Include additional negative controls (ideally quiescent cells lacking CDC45)

• Failed co-immunoprecipitation:

  • Try different lysis buffers with varying stringency

  • Add protein crosslinkers to stabilize transient interactions

  • Test different antibody amounts for optimal precipitation

  • Check if the epitope recognized by the antibody is masked in protein complexes

• Inconsistent results between experiments:

  • Standardize cell culture conditions to maintain consistent proliferation rates

  • Account for cell cycle variations in asynchronous populations

  • Use positive control lysates from validated cell lines (e.g., Jurkat, K562)

How can researchers quantitatively analyze CDC45 expression across different experimental conditions?

For quantitative analysis of CDC45 expression:

• Western blot quantification:

  • Use internal loading controls (β-actin, GAPDH) for normalization

  • Apply densitometry software to measure band intensity

  • Generate standard curves using recombinant CDC45 protein if absolute quantification is needed

  • Run biological replicates (n≥3) for statistical analysis

• Flow cytometry approaches:

  • Perform dual staining with cell cycle markers (e.g., propidium iodide, DAPI)

  • Use median fluorescence intensity (MFI) for quantitative comparisons

  • Include isotype controls and secondary-only controls

  • Apply compensation if using multiple fluorophores

• Immunofluorescence quantification:

  • Calculate nuclear:cytoplasmic intensity ratios

  • Measure total cellular fluorescence intensity

  • Use automated image analysis software for unbiased quantification

  • Analyze sufficient cell numbers (>100 cells) per condition

• qPCR correlation:

  • Compare protein levels with mRNA expression

  • Use validated CDC45-specific primers

  • Apply absolute quantification with standard curves

These approaches provide robust quantitative data when comparing CDC45 expression across experimental conditions .

What control samples are essential when designing experiments with CDC45 antibodies?

Essential controls for CDC45 antibody experiments include:

• Positive controls:

  • Proliferating cancer cell lines (293T, Jurkat, K562) known to express CDC45

  • S-phase enriched cell populations

  • Tissues with high proliferative indices (e.g., intestinal crypts, germinal centers)

• Negative controls:

  • Quiescent cells (serum-starved)

  • Terminally differentiated cells

  • Senescent cells

  • All three cellular states have been shown to lack CDC45 protein expression

• Antibody controls:

  • Isotype control antibodies

  • Secondary antibody-only samples

  • Blocking peptide competition assays to confirm specificity

• Experimental validation controls:

  • siRNA or shRNA knockdown of CDC45

  • Overexpression systems for antibody validation

  • Recombinant CDC45 protein as a reference standard

These comprehensive controls ensure experimental rigor and facilitate accurate interpretation of results across different applications.

How can CDC45 antibodies be utilized in single-cell analysis techniques?

CDC45 antibodies can be adapted for cutting-edge single-cell analyses through:

• Single-cell immunofluorescence:

  • Combine CDC45 staining with other replication markers

  • Correlate with DNA content measurement to identify S-phase cells

  • Apply computational image analysis for quantitative assessment

• Mass cytometry (CyTOF):

  • Label CDC45 antibodies with rare earth metals

  • Perform multi-parameter analysis with dozens of other cellular markers

  • Enable high-dimensional phenotyping of cellular subpopulations

• Single-cell Western blotting:

  • Detect CDC45 protein levels in individual cells

  • Correlate with other proteins of interest

  • Assess cell-to-cell variability in expression

• Microfluidic approaches:

  • Combine with live-cell imaging using fluorescently tagged CDC45 antibody fragments

  • Track CDC45 dynamics in real-time

  • Correlate with cellular behaviors and outcomes

These approaches provide unprecedented resolution of CDC45 biology at the single-cell level, revealing heterogeneity that might be masked in population-based analyses .

What are the methodological considerations for studying post-translational modifications of CDC45 using specific antibodies?

Studying CDC45 post-translational modifications requires:

• Selection of appropriate antibodies:

  • Use modification-specific antibodies (e.g., phospho-CDC45)

  • Verify specificity using dephosphorylation treatments

  • Consider generating custom antibodies against known modification sites

• Sample preparation:

  • Add phosphatase inhibitors to lysis buffers when studying phosphorylation

  • Include deubiquitinating enzyme inhibitors for ubiquitination studies

  • Consider crosslinking approaches to preserve transient modifications

• Enrichment strategies:

  • Perform phosphoprotein enrichment using TiO₂ or IMAC

  • Use ubiquitin affinity reagents for ubiquitinated forms

  • Apply immunoprecipitation with CDC45 antibodies followed by modification-specific detection

• Analytical approaches:

  • Combine with mass spectrometry for site identification

  • Use 2D gel electrophoresis to separate modified forms

  • Apply Phos-tag™ gels for separation of phosphorylated species

These methodological considerations allow researchers to investigate how post-translational modifications regulate CDC45 function throughout the cell cycle and in disease states.